Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether daily enoxaparin, added to low-dose aspirin, started before 14 weeks of gestation reduces placenta-mediated complications in pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation. METHODS: In this open-label multicenter randomized trial, we enrolled consenting pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation, gestational age at randomization of 7–13 weeks, singleton pregnancy, and no plan for anticoagulation. Eligible patients were randomly assigned to a one-to-one ratio to receive daily either 4,000 international units enoxaparin plus 100 mg aspirin or 100 mg aspirin alone. Randomization was done by a web-based randomization system. The primary composite outcome comprised maternal death, perinatal death, preeclampsia, small for gestational age (less than the 10th percentile), and placental abruption. A sample size of 232 women equally divided into two groups was needed to detect a significant reduction in primary outcome from 55% in the aspirin group to 36.7% in the enoxaparin-aspirin group (α: 0.05, β: 0.8, two-sided). RESULTS: Between November 14, 2009, and February 21, 2015, 257 participants were enrolled. Baseline demographic and clinical factors were similar between groups. Eight women were excluded after randomization (six in the enoxaparin–aspirin group and two in the aspirin group), leaving 124 participants assigned to enoxaparin–aspirin and 125 to aspirin. Five participants were lost to follow-up (two in the enoxaparin–aspirin group and three in the aspirin group). There was no significant difference between the groups in the primary outcome: enoxaparin–aspirin 42 of 122 (34.4%) compared with aspirin alone 50 of 122 (41%) (relative risk 0.84, 95% confidence interval 0.61–1.16, P=.29). The occurrence of complications did not differ between the two groups. CONCLUSION: Antepartum prophylactic enoxaparin does not significantly reduce placenta-mediated complications in women receiving low-dose aspirin for previous severe preeclampsia diagnosed before 34 weeks of gestation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00986765.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the use of low-molecularweight heparin has not been shown to reduce the risk of recurrent placenta-mediated pregnancy complications in at-risk women.75,77,78”
From Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction (2020) · cites this paper as [77]
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
(2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.107928 · Cited by 3,270
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., Forest, J.-C., & Giguère, Y. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181e9322a · Cited by 1,092
Greer, I. A., & Nelson-Piercy, C. (2005) · Blood · doi:10.1182/blood-2005-02-0626 · Cited by 797 · cited 1×
“Antepartum LMW heparin can be complicated by significant bleeding, generally associated with primary obstetric causes.(29) Although we observed a nonsignificant increase in wound hematoma, safety analysis of enoxaparin obtained in our study was reassuring.”
ResultLow-Dose Aspirin to Prevent Preeclampsia in Women at High Risk
Caritis, S., Sibai, B., Hauth, J., Lindheimer, M. D., Klebanoff, M., Thom, E., VanDorsten, P., Landon, M., Paul, R., Miodovnik, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381101 · Cited by 664
Hypertensive disorders in twin versus singleton gestations
Sibai, B. M., Hauth, J., Caritis, S., Lindheimer, M. D., MacPherson, C., Klebanoff, M., VanDorsten, J. P., Landon, M., Miodovnik, M., Paul, R., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70350-4 · Cited by 539
Sibai, B. M., El-Nazer, A., & Gonzalez-Ruiz, A. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90336-4 · Cited by 407
Gestational Outcome in Thrombophilic Women with Recurrent Pregnancy Loss Treated by Enoxaparin
Hoffman, R., Blumenfeld, Z., Weiner, Z., Younis, J. S., & Brenner, B. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613894 · Cited by 283
Research works printed but not linked: 1
- 2013, Hypertension in pregnancy. American College of Obstetricians and Gynecologists, Obstet Gynecol, 122, 1122
Cited by
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,191
Martins, J. G., Biggio, J. R., & Abuhamad, A. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.05.010 · Cited by 584
Tomimatsu, T., Mimura, K., Matsuzaki, S., Endo, M., Kumasawa, K., & Kimura, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174246 · Cited by 277
Groom, K. M., & David, A. L. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.565 · Cited by 170
Groom, K. M., McCowan, L. M., Mackay, L. K., Lee, A. C., Said, J. M., Kane, S. C., Walker, S. P., van Mens, T. E., Hannan, N. J., Tong, S., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.01.014 · Cited by 100
Metadata
- Authors
- Haddad, B., Winer, N., Chitrit, Y., Houfflin-Debarge, V., Chauleur, C., Bages, K., Tsatsaris, V., Benachi, A., Bretelle, F., Gris, J.-C., Bastuji-Garin, S., & for the Heparin-Preeclampsia (HEPEPE) Trial Investigators
- Affiliations
- Université Paris-Est Créteil (FR)
- ORCID
- Venue
- Obstetrics & Gynecology
- Published
- 2016-11
- Volume
- 128
- Issue
- 5
- Pages
- 1053-1063
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2531818013
- Semantic Scholar
- 1d4ab647beda89f0214204495f53de44aada7e1b
- Cited by
- 92
- References
- 34
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 9 · 2023: 6 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 15 · 2016: 1
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Maternal and fetal healthcare
- Keywords
- enoxaparin, low-dose aspirin, placenta-mediated pregnancy complications, preeclampsia recurrence, placental abruption, small for gestational age, maternal mortality, perinatal mortality, anticoagulation in pregnancy, thromboprophylaxis, pregnancy loss prevention
- MeSH terms
- Abruptio Placentae, Adult, Aspirin, Drug Therapy, Combination, Female, Humans, Pre-Eclampsia, Pregnancy, Enoxaparin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/aog.0000000000001673
- The paper
- Haddad, B., Winer, N., Chitrit, Y., Houfflin-Debarge, V., Chauleur, C., Bages, K., Tsatsaris, V., Benachi, A., Bretelle, F., Gris, J.-C., Bastuji-Garin, S., & for the Heparin-Preeclampsia (HEPEPE) Trial Investigators. (2016). Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001673
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.